Literature DB >> 1633513

Selective serotonin reuptake inhibitors.

J G Edwards.   

Abstract

Mesh:

Substances:

Year:  1992        PMID: 1633513      PMCID: PMC1882380          DOI: 10.1136/bmj.304.6843.1644

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  24 in total

1.  Fluvoxamine withdrawal syndrome.

Authors:  E Szabadi
Journal:  Br J Psychiatry       Date:  1992-02       Impact factor: 9.319

2.  The electrocardiogram as a tool for therapeutic monitoring: a critical analysis.

Authors:  S Guy; B Silke
Journal:  J Clin Psychiatry       Date:  1990-12       Impact factor: 4.384

3.  Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression.

Authors:  F W Reimherr; G Chouinard; C K Cohn; J O Cole; T M Itil; Y D LaPierre; H L Masco; J Mendels
Journal:  J Clin Psychiatry       Date:  1990-12       Impact factor: 4.384

4.  Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder.

Authors:  G Chouinard; W Goodman; J Greist; M Jenike; S Rasmussen; K White; E Hackett; M Gaffney; P A Bick
Journal:  Psychopharmacol Bull       Date:  1990

Review 5.  Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.

Authors:  K L Dechant; S P Clissold
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

6.  Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant.

Authors:  H Y Meltzer; M Young; J Metz; V S Fang; P M Schyve; R C Arora
Journal:  J Neural Transm       Date:  1979       Impact factor: 3.575

Review 7.  A review of fluvoxamine and its uses in depression.

Authors:  S W Burton
Journal:  Int Clin Psychopharmacol       Date:  1991-12       Impact factor: 1.659

8.  Overdose and safety with fluvoxamine.

Authors:  J A Henry
Journal:  Int Clin Psychopharmacol       Date:  1991-12       Impact factor: 1.659

Review 9.  Toleration and safety of sertraline: experience worldwide.

Authors:  D P Doogan
Journal:  Int Clin Psychopharmacol       Date:  1991-12       Impact factor: 1.659

10.  A comparison of paroxetine, imipramine and placebo in depressed out-patients.

Authors:  G C Dunbar; J B Cohn; L F Fabre; J P Feighner; R R Fieve; J Mendels; R K Shrivastava
Journal:  Br J Psychiatry       Date:  1991-09       Impact factor: 9.319

View more
  12 in total

1.  Selective serotonin reuptake inhibitors.

Authors:  D Harrison
Journal:  BMJ       Date:  1992-08-08

2.  Selective serotonin reuptake inhibitors.

Authors:  T Walley
Journal:  BMJ       Date:  1992-08-29

3.  Selective serotonin reuptake inhibitors.

Authors:  K Matthews; J M Eagles
Journal:  BMJ       Date:  1992-10-03

Review 4.  Recognition and management of depression in general practice: consensus statement.

Authors:  E S Paykel; R G Priest
Journal:  BMJ       Date:  1992-11-14

5.  Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin.

Authors:  E J Hatziandreu; R E Brown; D A Revicki; R Turner; J Martindale; S Levine; J E Siegel
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

6.  5-HT1A receptor antagonists increase the activity of serotonergic cells in the dorsal raphe nucleus in rats treated acutely or chronically with citalopram.

Authors:  L Arborelius; G G Nomikos; P Grillner; P Hertel; B B Höök; U Hacksell; T H Svensson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-08       Impact factor: 3.000

7.  Prescribing selective serotonin reuptake inhibitors as strategy for prevention of suicide.

Authors:  N Freemantle; A House; F Song; J M Mason; T A Sheldon
Journal:  BMJ       Date:  1994-07-23

Review 8.  Psychotropic drugs, aging and community care.

Authors:  M Philpot; A Puranik
Journal:  Drugs Aging       Date:  1994-10       Impact factor: 3.923

Review 9.  New or old antidepressants? Benefits of new drugs are exaggerated.

Authors:  D Owens
Journal:  BMJ       Date:  1994-11-12

Review 10.  Therapeutic drug monitoring for the treatment of psychiatric disorders. Clinical use and cost effectiveness.

Authors:  R Eilers
Journal:  Clin Pharmacokinet       Date:  1995-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.